Duke University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).

1,725 total trials 187 currently recruiting 1244 completed early-phase tilt top decile by trial count

Duke University: 1,725 sponsored US clinical trials, 187 recruiting.

Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,725 total, page 32 of 35

COMPLETED NA

Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence

NCT00672256

COMPLETED

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

NCT00636090

COMPLETED NA

Effect of Discontinuation of Sugar Sweetened Beverages

NCT00585897

COMPLETED NA

Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis

NCT00609687

COMPLETED NA

Developing Computer Based Treatments for Addiction

NCT00586534

TERMINATED NA

A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments

NCT00586417

TERMINATED Phase 2

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

NCT00510887

COMPLETED NA

A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic

NCT00606567

TERMINATED NA

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

NCT00399893

TERMINATED Phase 4

Combining Observational and Physiologic Sedation Assessment Tools

NCT00538369

TERMINATED Phase 4

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

NCT00369603

COMPLETED Phase 1

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

NCT00405678

COMPLETED NA

Retisert and Cataract Surgery in Patients With Severe Uveitis

NCT00570830

COMPLETED Phase 4

Responses of Myocardial Ischemia to Escitalopram Treatment

NCT00574847

COMPLETED

Duke Conte Center for the Neuroscience of Depression in Late Life

NCT00576875

COMPLETED Phase 1

Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates

NCT00462098

COMPLETED NA

Showing Health Information Value in a Community Network

NCT00365885

COMPLETED Phase 4

Study of the Insomnia in Patients With Low Back Pain

NCT00365976

COMPLETED Phase 1

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807

COMPLETED Phase 3

Exercise to Treat Depression in Individuals With Coronary Heart Disease

NCT00302068

COMPLETED Phase 2

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

NCT00672594

TERMINATED Phase 2

Sorafenib in Myelodysplastic Syndrome

NCT00510289

COMPLETED

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

NCT00237328

COMPLETED NA

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

NCT00323258

TERMINATED Phase 2

DepoCyt for Active Lymphomatous or Leukemic Meningitis

NCT00523939

COMPLETED Phase 2

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

NCT00324454

COMPLETED Phase 2

Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia

NCT00321451

COMPLETED Phase 2

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

NCT00301873

COMPLETED NA

An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients

NCT00734955

COMPLETED NA

3-D Transcranial Ultrasound Analysis Study

NCT00239525

TERMINATED Phase 2

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

NCT02157116

COMPLETED Phase 3

Locomotor Experience Applied Post Stroke Trial

NCT00243919

COMPLETED Phase 1

A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas

NCT00314808

COMPLETED Phase 4

TissueLink Study During Multi-Level Spine Surgery

NCT01300559

COMPLETED Phase 2

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

NCT00352521

TERMINATED Phase 1

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

NCT00346229

TERMINATED Phase 4

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613

COMPLETED Phase 4

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

NCT00573261

COMPLETED NA

Feasibility of Exercise With Post-Op Lung Cancer Patients

NCT00636571

COMPLETED Phase 1

Study to Prevent Cartilage Damage Following Acute Knee Injury.

NCT00332254

COMPLETED Phase 4

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

NCT00335270

COMPLETED Phase 2

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

NCT00615927

COMPLETED Phase 1

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871

COMPLETED NA

Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

NCT00734838

COMPLETED NA

Zonisamide for Weight Reduction in Obese Adults

NCT00275834

COMPLETED

Antimicrobial PK in Infants With Suspected or Confirmed Infection

NCT00491426

COMPLETED

DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)

NCT00600392

COMPLETED Phase 2

Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide

NCT00616005

COMPLETED Phase 2

Levetiracetam in Post-Traumatic Stress Disorder

NCT00413296

TERMINATED Phase 2

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

NCT00299611

← Previous Page 32 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 136
Phase 2 175
Phase 3 41
Phase 4 134

What is open in the Duke University pipeline

187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).

Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Duke University: open-pipeline peers nationwide

Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Duke UniversityUniversity of California, San FranciscoStanford UniversityVA Office of Research and DevelopmentPfizerCarnegie Mellon UniversityCAMC Health SystemUConn HealthHartford Hospital
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,725 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Duke University page

1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.

  • 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.